Trial Profile
Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Purine nucleoside phosphorylase (Primary) ; Fludarabine
- Indications Head and neck cancer; Pharyngeal neoplasms; Salivary gland cancer; Squamous cell cancer; Tongue cancer
- Focus Adverse reactions; Registrational
- Sponsors GeoVax Labs
- 04 Jan 2024 According to a GeoVax Labs media release, the company expect to complete the study by the third quarter of this year.
- 04 Jan 2024 According to a GeoVax Labs media release, announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin in patients suffering from advanced head and neck cancer.
- 09 Nov 2023 According to a GeoVax Labs media release, the company is preparing to announce updates from this trial in the coming months